Anika Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $120.7M+0.6% YoYTTM through 30 Jun 2026
Net Income -$3.8MTTM through 30 Jun 2026
Free Cash Flow $562KTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 57.0% |
| EBITDA Margin | 0.4% |
| Operating Margin | -9.8% |
| Net Margin | -3.1% |
Returns
-7.7%ROE
-2.1%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio4.72x
Net Debt-$57.5Mnet cash position
Cash & Equivalents$38.4M
Quality Metrics
Altman Z-Score5.15
Piotroski F-Score5 / 9
FCF Margin0.5%
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $112.8M
Diluted EPS-$0.27TTMFY2025: $-0.76
Dividend
No dividend
Capital Allocation
R&D Spend$27.5M
Capex Intensity4.5%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Commercial Channel | $48.4M | +15.0% | View detailsRemains the primary engine of growth with accelerating adoption of the Integrity Implant System. |
| OEM Channel | $64.4M | -17.0% | View detailsExpected to remain highly cash-generative despite U.S. pricing dynamics. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.